AMT's Lead Product Poised to Address Major Liver Disease
European Patent Office Grants Patent for Treatment of Non-alcoholic Steatotic Hepatitis
AMT-011 is currently in its last phase of clinical development for the treatment of lipoprotein lipase (LPL) deficiency that is associated with very high circulating triglyceride (fat) levels. The product consists of an AAV-based vector that delivers the LPL gene to the muscle, leading to long-term expression of the therapeutic protein, lipoprotein lipase.
The patented invention is related to the observation that expression of AMT-011 in muscle causes a reduction of the liver triglyceride content by redistributing triglycerides from the liver to the peripheral muscles where it is metabolized. NAFLD and NASH are closely related to the pathogenesis of the "metabolic syndrome". This latter condition is characterized by central obesity, increase of serum triglycerides and insulin resistance, and is a major cause of diabetes and coronary vascular disease in the Western world.
Ronald Lorijn, CEO of AMT, said, "We are very pleased that EPO granted this important patent to AMT. This substantially widens the potential use of our lead product AMT-011 beyond the current orphan indications to the large patient populations who suffer from fatty liver diseases, hypertriglyceridemia and insulin resistance. In the course of 2008, it is our intention to initiate a development track for AMT-011 in NASH to establish proof of concept in man."
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.